Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Fisman, David N ^a   Tuite, Ashleigh R ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; TRIPLE VACCINE;

AGE DISTRIBUTION; ARTICLE; CALIBRATION; CANADA; COMPARTMENT MODEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG INDICATION; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH PROGRAM; INFLUENZA; INFLUENZA VACCINATION; OUTCOME ASSESSMENT; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; ADOLESCENT; ADULT; AGED; BIOLOGICAL MODEL; CHILD; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH; HUMAN; IMMUNOLOGY; INFANT; METHODOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; QUALITY OF LIFE; STATISTICS; TIME; VACCINATION;

ORTHOMYXOVIRIDAE;

ADOLESCENT; ADULT; AGED; CALIBRATION; CANADA; CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; HEALTH; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; MODELS, BIOLOGICAL; QUALITY OF LIFE; TIME FACTORS; VACCINATION; YOUNG ADULT;

EID: 81055145746     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027420     Document Type: Article

References (47)

1. Schanzer DL, Tam TW, Langley JM, Winchester BT, (2007) Influenza-attributable deaths, Canada 1990-1999. Epidemiol Infect 135: 1109-1116.
2. Cox NJ, Subbarao K, (1999) Influenza. Lancet 354: 1277-1282.
3. Postma MJ, Jansema P, van Genugten ML, Heijnen ML, Jager JC, et al. (2002) Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 62: 1013-1024.
4. O'Reilly FW, Stevens AB, (2002) Sickness absence due to influenza. Occup Med (Lond) 52: 265-269.
5. Keech M, Scott AJ, Ryan PJ, (1998) The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond) 48: 85-90.
6. Rivetti D, Jefferson T, Thomas R, Rudin M, Rivetti A, et al. (2006) Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev 3: CD004876.
7. Goodwin K, Viboud C, Simonsen L, (2006) Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine 24: 1159-1169.
8. Podda A, (2001) The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine 19: 2673-2680.
9. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kleninger-Baum D, et al. (2010) Efficacy of an MF59-adjuvanted seasonal influenza vaccine versus non-adjuvanted influenza vaccine and control vaccine in 6 to <72 month old children. Infectious Disease Society of America 48th Annual Meeting, 21-24 October, 2010 Vancouver, Canada.
10. Mannino S, Villa M, Weiss N, Apolone G, Rothman KJ, (2010) Effectiveness of influenza vaccination with Fluad versus a sub-unit influenza vaccine. Abstracts of the 43rd Annual Meeting of the Society for Epidemiologic Research, 23-26 June, Anaheim, California. Am J Epidemiol 171: S157.
11. Vesikari T, Knuf M, Wutzler P, Karvonen A, Kieninger-Baum D, et al. (2011) Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 365: 1406-1416.
12. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, et al. (2010) Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2: 15ra15.
13. Ansaldi F, Bacilieri S, Durando P, Sticchi L, Valle L, et al. (2008) Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 26: 1525-1529.
14. Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, et al. (2009) Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 28: 563-571.
15. Tuite AR, Fisman DN, Kwong JC, Greer AL, (2010) Optimal pandemic influenza vaccine allocation strategies for the Canadian population. PLoS One 5: e10520.
16. Tuite A, Fisman DN, Kwong JC, Greer A, (2009) Seasonal Influenza Vaccine Allocation in the Canadian Population during a Pandemic. PLoS Curr Influenza pp. RRN1143.
17. Kwong JC, Stukel TA, Lim J, McGeer AJ, Upshur RE, et al. (2008) The effect of universal influenza immunization on mortality and health care use. PLoS Med 5: e211.
18. Sander B, Kwong JC, Bauch CT, Maetzel A, McGeer A, et al. (2010) Economic appraisal of Ontario's Universal Influenza Immunization Program: a cost-utility analysis. PLoS Med 7: e1000256.
19. Praditsuwan R, Assantachai P, Wasi C, Puthavatana P, Kositanont U, (2005) The efficacy and effectiveness of influenza vaccination among Thai elderly persons living in the community. J Med Assoc Thai 88: 256-264.
20. Jefferson T, Di Pietrantonj C, Al-Ansary LA, Ferroni E, Thorning S, et al. (2010) Vaccines for preventing influenza in the elderly. Cochrane Database Syst Rev pp. CD004876.
21. Heinonen S, Silvennoinen H, Lehtinen P, Vainionpaa R, Ziegler T, et al. (2011) Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis 11: 23-29.
22. Sander B, Bauch CT, Fisman D, Fowler RA, Kwong JC, et al. (2010) Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience. Vaccine 28: 6210-6220.
23. O'Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G, (2011) MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev Vaccines 10: 447-462.
24. Loeb M, Russell ML, Moss L, Fonseca K, Fox J, et al. (2010) Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 303: 943-950.
25. King JC Jr, Stoddard JJ, Gaglani MJ, Moore KA, Magder L, et al. (2006) Effectiveness of school-based influenza vaccination. N Engl J Med 355: 2523-2532.
26. World Health Organization (2011) Choosing interventions that are cost effective: cost-effectiveness thresholds. 21 Available: http://www.who.int/choice/costs/CER_thresholds/en/index.html. Accessed 2011 Aug.
27. Beyer WE, Nauta JJ, Palache AM, Giezeman KM, Osterhaus AD, (2011) Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine 29: 5785-5792.
28. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, et al. (2009) Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 361: 2424-2435.
29. Simonsen L, Fukuda K, Schonberger LB, Cox NJ, (2000) The impact of influenza epidemics on hospitalizations. J Infect Dis 181: 831-837.
30. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, et al. (1998) Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 178: 53-60.
31. Reichert TA, Simonsen L, Sharma A, Pardo SA, Fedson DS, et al. (2004) Influenza and the winter increase in mortality in the United States, 1959-1999. Am J Epidemiol 160: 492-502.
32. Dushoff J, Plotkin JB, Viboud C, Earn DJ, Simonsen L, (2006) Mortality due to influenza in the United States-an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 163: 181-187.
33. Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, et al. (1994) The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA 272: 1661-1665.
34. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, et al. (2005) Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med 165: 265-272.
35. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS, (2006) Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol 35: 337-344.
36. Jackson ML, Weiss NS, Nelson JC, Jackson LA, (2007) To rule out confounding, observational studies of influenza vaccine need to include analyses during the "preinfluenza period". Arch Intern Med 167: 1553-1554 author reply 1554-1555.
37. Khurana S, Verma N, Yewdell JW, Hilbert AK, Castellino F, et al. (2011) MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci Transl Med 3: 85ra48.
38. Dormitzer PR, Galli G, Castellino F, Golding H, Khurana S, et al. (2011) Influenza vaccine immunology. Immunol Rev 239: 167-177.
39. Black S, Della Cioppa G, Malfroot A, Nacci P, Nicolay U, et al. (2010) Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 28: 7331-7336.
40. Zarocostas J, (2011) WHO backs further probes into possible link between H1N1 vaccine and narcolepsy in children. BMJ 342: d909.
41. Montastruc JL, Durrieu G, Rascol O, (2011) Pandemrix, (H1N1)v influenza and reported cases of narcolepsy. Vaccine 29: 2010.
42. Dauvilliers Y, Montplaisir J, Cochen V, Desautels A, Einen M, et al. (2010) Post-H1N1 narcolepsy-cataplexy. Sleep 33: 1428-1430.
43. Tsai TF, Crucitti A, Nacci P, Nicolay U, Cioppa GD, et al. (2011) Explorations of clinical trials and pharmacovigilance databases of MF59((R))-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 43: 702-706.
44. Statistics Canada, (2007) Age and sex highlight tables, 2006 Census. 21 Available: http://www12.statcan.gc.ca/census-recensement/2006/dp-pd/hlt/97-551/index.cfm?Lang=E. Accessed 2009 Aug.
45. Statistics Canada, (2006) Complete life table, Canada, 2000 to 2002. 13 Available: http://www.statcan.gc.ca/pub/84-537-x/4064441-eng.htm. Accessed 2010 Aug.
46. Tuite AR, Greer AL, Whelan M, Winter AL, Lee B, et al. (2010) Estimated epidemiologic parameters and morbidity associated with pandemic H1N1 influenza. CMAJ 182: 131-136.
47. Moran K, Maaten S, Guttmann A, Northrup D, Kwong JC, (2009) Influenza vaccination rates in Ontario children: implications for universal childhood vaccination policy. Vaccine 27: 2350-2355.